Intellectual Product – Page 3 – Talk Bio

Actionable Insights Powered by AI

Trump Administration Cancels Major Federal Funding for Moderna’s Bird Flu Vaccine

1 month ago talkbio0Tagged Administration occupational activities, bird flu vaccine, cancellation, CHARGE Syndrome, H5 avian influenza, HHS, Moderna, mRNA Vaccine, pandemic preparedness, Transplant Registry Unified Management Program

Trump administration; Moderna; bird flu vaccine; HHS; funding cancellation; mRNA vaccine; pandemic preparedness; H5 avian influenza

iTeos to Shut Down Operations After TIGIT Therapy Setback

1 month ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

Uncertainty Surrounds Moderna’s Next-Generation COVID Shot Amid Policy Changes

1 month ago talkbio0Tagged COVID19 (disease), flu/COVID-19, Moderna, Policy, Recommendation, Regulatory Setback, United States Food and Drug Administration, vaccine access, Vaccines

Moderna; COVID-19 vaccine; FDA policy; combination flu/COVID-19 shot; vaccine access; mRNA-1083; vaccine recommendations; regulatory setback

Trump Taps Dr. Oz as Lead Negotiator for ‘Most Favored Nation’ Drug Pricing Policy

1 month ago talkbio0Tagged Dr., Drug Costs, drug price, Health Policy, Myasthenic Syndromes, Congenital, Nation, ounce, pharmaceutical negotiations, Transplant Registry Unified Management Program

Trump; Dr. Mehmet Oz; Most Favored Nation; drug pricing; CMS; pharmaceutical negotiations; healthcare policy; drug costs

Sernova Chair Resigns After Insider Trading Indictment Tied to Novartis-Chinook Deal

1 month ago talkbio0Tagged biotherapeutics, DOJ, indictment, insider trading, News [Publication Type], Novartis-Chinook acquisition, resignation, Ross Haghighat, securities fraud, Sernova

Sernova Biotherapeutics; insider trading; resignation; Ross Haghighat; Novartis-Chinook acquisition; securities fraud; biotech news; DOJ indictment

GLP-1s May Lower Cancer Risk; Gyre Stock Drops After Hep B Data, Share Offering

2 months ago talkbio0Tagged agonists, Cancer Risk, Clinical Data, GLP-1 receptor, Gyre stock, Hepatitis B, Mortality Vital Statistics, Obesity-Related Cancers

GLP-1 receptor agonists; cancer risk; obesity-related cancers; Gyre stock; hepatitis B; clinical data; mortality

Will Trump’s Tax Bill Cut Medicare by $490 Billion? Not Exactly.

2 months ago talkbio0Tagged Beak, Budgets, CBO, healthcare changes, Medicare, reconciliation, Sequestration, Transplant Registry Unified Management Program

Trump tax bill; Medicare cuts; sequestration; budget reconciliation; 2025 healthcare changes; CBO report

Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application

2 months ago talkbio0Tagged Biologics License Application, Clinical Trials, COVID19 (disease), Effectiveness, Influenza, Moderna, mRNA-1083, Prices, United States Food and Drug Administration, Vaccines, Vaccines, Combined

Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price

Vinay Prasad’s First Major Policy: Challenging Covid Vaccine ‘Dogma’ at FDA

2 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), Policy, Prasad, public health medicine (field), Recommendation, Regulatory Framework, United States Food and Drug Administration, Vaccines, Vinay

Vinay Prasad; FDA; Covid-19 vaccines; policy change; clinical trials; vaccine recommendations; public health; regulatory framework

FDA Institutes Stricter, Targeted COVID Vaccine Policy, Moving Away from ‘One-Size-Fits-All’ Approach

2 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), Elderly (population group), Eligibility Determination, high-risk groups, Policy, public health medicine (field), United States Food and Drug Administration, Vaccines

FDA; COVID-19; vaccine policy; vaccine eligibility; clinical trials; high-risk groups; elderly; policy change; public health